Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene.

The ability to sequence a large number of DNA samples rapidly and accurately for detection of all possible mutations is a critical goal for the future application of DNA sequencing in routine medical diagnostics. Pyrosequencing() is a non-electrophoretic real-time DNA sequencing method that uses the luciferase-luciferin light release as the detection signal for nucleotide incorporation into target DNA. For pyrosequencing of the human p53 gene, a nested multiplex PCR method for amplification of exons 5-8 was prepared. In order to investigate the use of pyrosequencing in mutation detection, DNA samples from skin-cancer patients were used. Two forms of nucleotide dispensation strategy were used, cyclic and programmed. Bi-directional pyrosequencing was performed and the overlapping sequence data produced were assembled to determine the sequence of the gene. Reliable sequencing data were obtained with both dispensation strategies, but some advantages were obtained using the programmed nucleotide dispensation approach, such as longer and faster reads, and fewer out-of-phase problems. The accuracy of pyrosequencing for detection of p53 mutations and allele distribution was demonstrated.

[1]  F. Pontén,et al.  Direct solid-phase sequence analysis of the human p53 gene by use of multiplex polymerase chain reaction and alpha-thiotriphosphate nucleotides. , 1995, Clinical chemistry.

[2]  R A Gibbs,et al.  Termination of DNA synthesis by novel 3'-modified-deoxyribonucleoside 5'-triphosphates. , 1994, Nucleic acids research.

[3]  R. Drmanac,et al.  DNA sequencing by hybridization: 100 bases read by a non-gel-based method. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[5]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[6]  E. Feinstein,et al.  Expression of the normal p53 gene induces differentiation of K562 cells. , 1992, Oncogene.

[7]  F. Pontén,et al.  Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin. , 1997, The American journal of pathology.

[8]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[9]  F. Pontén,et al.  Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. , 1994, BioTechniques.

[10]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Yaniv,et al.  Wild-type p53 can down-modulate the activity of various promoters. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[13]  F Hillenkamp,et al.  Infrared MALDI mass spectrometry of large nucleic acids. , 1998, Science.

[14]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[15]  A. Levine,et al.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. , 1994, British Journal of Cancer.

[16]  M Ronaghi,et al.  Analyses of secondary structures in DNA by pyrosequencing. , 1999, Analytical biochemistry.

[17]  S. Peller.  Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. , 1998, Seminars in cancer biology.

[18]  M. Oren.  Relationship of p53 to the control of apoptotic cell death. , 1994, Seminars in cancer biology.

[19]  J. Cunningham,et al.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.

[20]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Van Montagu,et al.  Gene discovery in the wood-forming tissues of poplar: analysis of 5, 692 expressed sequence tags. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Lawrence,et al.  Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro , 1994, Journal of the Neurological Sciences.

[23]  Mansur Cp.  The regulation and function of the p53 tumor suppressor. , 1997 .

[24]  D. Givol,et al.  The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Thierry Soussi,et al.  Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects , 1997, Nucleic Acids Res..

[26]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[27]  M. Ronaghi,et al.  Production, Purification, and Luminometric Analysis of RecombinantSaccharomyces cerevisiae MET3Adenosine Triphosphate Sulfurylase Expressed inEscherichia coli , 1999 .

[28]  J. Bergh,et al.  Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. , 1998, Clinical chemistry.